Satumomab Biosimilar – Anti-TAG-72 mAb – Research Grade

Introduction to Satumomab Biosimilar – Anti-TAG-72 mAb

Satumomab Biosimilar is a monoclonal antibody (mAb) that targets a protein called TAG-72. This protein is overexpressed in various types of cancer, making it a promising therapeutic target for cancer treatment. Satumomab Biosimilar is a research grade version of the original Satumomab, which has been developed as a biosimilar to provide a more affordable option for researchers studying TAG-72 and its potential as a therapeutic target.

Structure of Satumomab Biosimilar

Satumomab Biosimilar is a recombinant, humanized monoclonal antibody that is produced in a mammalian cell expression system. It is composed of two identical heavy chains and two identical light chains, with a total molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) at the tips of the Y and a crystallizable fragment (Fc) at the base. The Fab regions are responsible for binding to TAG-72, while the Fc region is involved in immune effector functions.

Mechanism of Action

Satumomab Biosimilar works by specifically binding to TAG-72, a protein that is overexpressed on the surface of many cancer cells. This binding triggers a series of events that ultimately lead to the destruction of the cancer cells. One of the main mechanisms of action of Satumomab Biosimilar is antibody-dependent cell-mediated cytotoxicity (ADCC), where the Fc region of the antibody binds to immune cells, such as natural killer cells, triggering them to attack and kill the cancer cells.

Title: Applications of Satumomab Biosimilar

Satumomab Biosimilar has shown promising results in preclinical studies as a potential therapeutic agent for various types of cancer, including ovarian, colon, and breast cancer. Its ability to specifically target TAG-72, which is overexpressed in these cancers, makes it a promising candidate for targeted cancer therapy. Additionally, Satumomab Biosimilar has also been used in diagnostic applications, such as in the detection of TAG-72 in cancer cells.

Advantages of Satumomab Biosimilar

As a biosimilar, Satumomab Biosimilar offers several advantages over the original Satumomab. First and foremost, it is more affordable, making it more accessible to researchers studying TAG-72 and its potential as a therapeutic target. Additionally, Satumomab Biosimilar has been shown to have similar efficacy and safety profiles as the original Satumomab, making it a reliable alternative for preclinical studies.

Future Directions

The development of Satumomab Biosimilar has opened up new possibilities for research on TAG-72 and its potential as a therapeutic target for cancer treatment. As more studies are conducted, it is hoped that Satumomab Biosimilar will pave the way for the development of novel therapies that specifically target TAG-72, leading to more effective and less toxic treatments for cancer patients.

Conclusion

In conclusion, Satumomab Biosimilar is a research grade monoclonal antibody that specifically targets TAG-72, a protein that is overexpressed in various types of cancer. Its Y-shaped structure and mechanism of action make it a promising candidate for targeted cancer therapy. As a biosimilar, it offers several advantages over the original Satumomab, making it a valuable tool for researchers studying TAG-72 and its potential as a therapeutic target. With further research and development, Satumomab Biosimilar has the potential to revolutionize cancer treatment.

ProteoGenix catalogue number PX-TA1098. For research use only.

Target: Satumomab Biosimilar – Anti-TAG-72 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet

Download the manufacturer safety data sheet (MSDS/SDS)